Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort by Cumming, Sarah A. et al.
ARTICLE OPEN ACCESS
Genetic determinants of disease severity in the
myotonic dystrophy type 1 OPTIMISTIC cohort
Sarah A. Cumming, PhD, Cecilia Jimenez-Moreno, PhD, Kees Okkersen, MD, Stephan Wenninger, MD,
Ferroudja Daidj, MD, Fiona Hogarth, PhD, Roberta Littleford, PhD, Gra´inne Gorman, MD,
Guillaume Bassez, MD, Benedikt Schoser, MD, Hanns Lochmu¨ller, MD, Baziel G.M. van Engelen, MD, PhD, and
Darren G. Monckton, PhD, on behalf of the OPTIMISTIC Consortium
Neurology® 2019;93:e995-e1009. doi:10.1212/WNL.0000000000008056
Correspondence
Dr. Monckton
darren.monckton@
glasgow.ac.uk
Abstract
Objective
To evaluate the role of genetic variation at the DMPK locus on symptomatic diversity in 250
adult, ambulant patients with myotonic dystrophy type 1 (DM1) recruited to the Observational
Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life—Standards,
a Target Identiﬁcation Collaboration (OPTIMISTIC) clinical trial.
Methods
We used small pool PCR to correct age at sampling biases and estimate the progenitor allele
CTG repeat length and somatic mutational dynamics, and AciI digests and repeat primed PCR
to test for the presence of variant repeats.
Results
We conﬁrmed disease severity is driven by progenitor allele length, is further modiﬁed by age,
and, in some cases, sex, and that patients in whom the CTG repeat expands more rapidly in the
soma develop symptoms earlier than predicted. We revealed a key role for variant repeats in
reducing disease severity and quantiﬁed their role in delaying age at onset by approximately
13.2 years (95% conﬁdence interval 5.7–20.7, 2-tailed t test t = −3.7, p = 0.0019).
Conclusions
Careful characterization of the DMPK CTG repeat to deﬁne progenitor allele length and
presence of variant repeats has increased utility in understanding clinical variability in a trial
cohort and provides a genetic route for deﬁning disease-speciﬁc outcome measures, and the
basis of treatment response and stratiﬁcation in DM1 trials.
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Myotonic dystrophy type 1 (DM1) is a highly variable
autosomal dominant inherited disorder aﬀecting individu-
als of both sexes and all ages.1 DM1 is caused by the ex-
pansion of a CTG repeat in the DMPK gene that varies in
length from under 40 repeats in the general population to
more than 1,000 repeats in some patients.2–7 Longer CTG
tracts are associated with more severe disease and earlier
age at onset.8–11 However, genotype to phenotype rela-
tionships determined using the traditional diagnostic test
have low predictive value and the International Myotonic
Dystrophy Consortium recommends that families are not
oﬀered predictive phenotypic information based on the size
of the CTG repeat.12
Expanded disease-causing alleles are highly unstable and
usually increase in length during intergenerational
transmission,8,13–15 explaining the decrease in age at onset
of 20–30 years per generation typically observed in DM1
families.16 The expanded CTG is also highly unstable in the
soma in a process that is expansion-biased, age-dependent,
and tissue-speciﬁc.17–24 Thus, the average length of the
CTG repeat measured using the traditional diagnostic
depends on the age at which the sample was taken. Pre-
viously, we demonstrated that a sensitive small pool PCR
(SP-PCR) analysis of blood DNA could be used to estimate
the progenitor allele length (ePAL), i.e., the length of the
CTG repeat transmitted to the individual by the aﬀected
parent.18 In addition, we demonstrated that ePAL could
reduce the confounding eﬀects of age at sampling inherent
in the traditional test and we could dramatically improve the
ability to predict age at onset in DM1.25,26
Observational Prolonged Trial in Myotonic Dystrophy Type
1 to Improve Quality of Life—Standards, a Target Identiﬁ-
cation Collaboration (OPTIMISTIC) was a large in-
ternational, multicenter, model-based randomized trial
designed to compare the utility of tailored cognitive be-
havioral therapy (CBT) with an optional graded exercise
plan against standard care.27,28 In order to provide additional
insight into the genetic basis of variability in DM1 and as
a route toward genetic stratiﬁcation in clinical trials, we
sought to estimate the progenitor allele length and deﬁne the
repeat dynamics of the DM1 CTG repeat in the blood DNA
of participants recruited to OPTIMISTIC.
Methods
Standard protocol approvals, registrations,
and patient consents
Full details of the OPTIMISTIC protocol, including power
calculations for sample size, have been reported previously
(Clinicaltrials.gov, NCT02118779).27 All participants were
recruited with informed consent. The protocol was approved
by the National Research Ethics Service Committee North
East—Sunderland (UK), the Comite de Protection des Per-
sonnes ile de France V (France), the Ethikkommission bei der
LMUMu¨nchen (Germany), and the Concernstaf Kwaliteit en
Veiligheid Commissie Mensgebonden Onderzoek Regio
Arnhem-Nijmegen (Netherlands).
Phenotypic data
Ambulant adult patients (>18 years of age) with genetically
proven DM1 capable of providing informed consent with
severe fatigue (Checklist Individual Strength–Fatigue [CIS-
Fatigue] score ≥35) were recruited between April 2014 and
May 2015 through 4 clinical centers: Nijmegen, the Nether-
lands; Paris, France; Munich, Germany; and Newcastle,
United Kingdom (n = 255 [46.3% female] [118/255]).27,28
Exclusion criteria included neurologic or orthopedic comor-
bidity possibly inﬂuencing the intervention or outcomes; use
of psychotropic drugs (except modaﬁnil, Ritalin, and anti-
depressants, where the dosing regimen was stable for at least
12 months prior to screening); severe depression; participa-
tion in another interventional clinical trial; or inability to
complete study questionnaires. Age at onset of DM1 symp-
toms was obtained during the trial recruitment screening visit
in answer to the question “At what age did the ﬁrst medical
problems occur that may be related to your myotonic dys-
trophy?” With the exception of patients recruited through
Munich, age at sampling was calculated based on known date
of birth and the date of visit 2, at which the blood sample was
provided. As a local regulatory requirement, date of birth was
not recorded for participants recruited in Munich, therefore
the age at sampling used was self-reported by participants at
visit 2. Additional baseline (visit 2) clinical measures were
obtained as described in the OPTIMISTIC protocol and
reported previously.27,28 The majority of participants (n =
225) were not known to be related. Eight parent–oﬀspring
pairs, 4 sibling pairs, and 3 trios of 2 siblings and 1 oﬀspring
were also recruited.
Glossary
6-MWT = 6-Minute Walk Test; ASBQ = Adult Social Behavior Questionnaire; BDI-fs = Beck Depression Inventory—fast
screen; CBT = cognitive behavioral therapy; CI = conﬁdence interval; CIS-fatigue = Checklist Individual Strength Fatigue
score;DM1 = myotonic dystrophy type 1; ePAL = estimated progenitor allele length; FDSS = Fatigue and Daytime Sleepiness
Scale;MIRS =Muscle Impairment Rating Scale;OPTIMISTIC =Observational Prolonged Trial in Myotonic Dystrophy Type
1 to Improve Quality of Life—Standards, a Target Identiﬁcation Collaboration; RP-PCR = repeat-primed PCR; SP-PCR =
small pool PCR; SSL = van Sonderen Social Support List; SSL-D = van Sonderen Social Support List—Discrepancies; SSL-I =
van Sonderen Social Support List—Interactions; SSL-N = van Sonderen Social Support List—Negative Interactions; TMT =
Trail-Making Test.
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DNA samples
A 10-mL venous blood sample was taken from OPTIMISTIC
participants at baseline (time point V2). Blood was collected
into EDTA tubes and stored locally at −80°C. Frozen blood
was shipped on dry ice to the Newcastle Biobank for Research
of Neuromuscular Disorders,29 where DNA was isolated and
shipped to the University of Glasgow. Baseline DNA samples
were available from 250 out of 255 OPTIMISTIC partic-
ipants. Historical DNA samples from OPTIMISTIC partic-
ipants collected during routine molecular diagnosis (from 6
months to 21 years previously) were available for 71 partic-
ipants and obtained from local diagnostic laboratories via the
Newcastle Biobank. Historical DNA samples were not avail-
able for the 5 participants without baseline DNA samples.
SP-PCR and AciI digestion
SP-PCR was carried out using ﬂanking primers DM-C and
DM-DR as previously described18,30 using Custom PCR
Master Mix (Thermo Fisher Scientiﬁc [Waltham, MA] #SM-
0005) supplemented with 69 mM 2-mercaptoethanol. Taq
polymerase (Sigma-Aldrich UK, Gillingham) was used at 1
unit per 10 μL. Where required, reactions were supple-
mented with 10% DMSO and the annealing temperature
reduced to 63.5°C. PCR products were digested with AciI
(New England Biolabs UK, Hitchin) in accordance with the
manufacturer’s instructions. DMSO was removed prior to
AciI digestion using the QIAquick (Qiagen, Venlo, the
Netherlands) PCR puriﬁcation kit. DNA fragments were
resolved by agarose gel electrophoresis and Southern blot
hybridized as described.18,30 Autoradiographic images were
scanned and ePAL and modal allele lengths were estimated
from the lower boundary18 and the densest part of the ex-
panded allele distribution respectively by comparison
against the molecular weight ladder, using CLIQS 1D gel
analysis software (TotalLab UK, Newcastle upon Tyne).
Repeat-primed PCR (RP-PCR)
RP-PCR was performed at the 59-end of the repeat tract
using 1 μM DM-A, 0.1 μM TAG-CAG5, and 1 μM TAG
primer and at the 39-end of the repeat tract using 1 μMDM-
DR, 0.1 μM TAG-CTG5, and 1 μM TAG primer, as de-
scribed previously.31
Statistical analysis
Statistical analyses were undertaken in R (version 3.4.3)32
using RStudio (version 1.0.153).33 There were no repeated
measures and all individuals are represented once in each
statistical analysis. All statistical analyses were 2-sided. Log
transformations of the age at onset, degree of somatic in-
stability, and Stroop interference score were used to better
approximate a normal distribution andminimize the inﬂuence
of extreme values. Participants with missing data were ex-
cluded from relevant analyses. Multiple linear regressions
were performed using the lm function from the R Stats
package. In all regression analyses, we report the adjusted r2,
the p value for the overall model, and the coeﬃcient (β) and p
value for each measure. Model selection was based on the
Akaike information criterion for each model using a back-
wards stepwise selection procedure implemented using the
step function in R.34 Conﬁdence intervals (CI) (95%) for
point estimates were calculated where appropriate.
Data availability
The de-identiﬁed participant genetic data presented here are
available online (datadryad.org/review?doi=doi:10.5061/
dryad.t063q70). Requests to access the de-identiﬁed partici-
pant data from the main OPTMISTIC trial should be
addressed to the trial chief investigator Dr. Baziel van Engelen
(baziel.vanengelen@radboudumc.nl).
Results
Estimation of progenitor and modal allele CTG
repeat lengths in the OPTIMISTIC cohort
In order to investigate genetic variation in the OPTIMISTIC
cohort, we used SP-PCR18 to determine the ePAL, modal
allele length at recruitment, and where available (71 partic-
ipants), modal allele length at molecular diagnosis for the
expanded CTG repeatDMPK allele (ﬁgure 1A). An expanded
DMPK CTG repeat allele was readily detected in 241 out of
250 participants using our standard SP-PCR procedure. In an
additional 7 participants, an expanded allele was only detected
after the addition of 10% DMSO to the PCR, consistent with
the presence of GC-rich variant repeats.31 In one of these
individuals, even in the presence of DMSO, only a small
number of expanded alleles was successfully ampliﬁed relative
to the non-disease-associated allele and it was not possible to
deﬁne the ePAL or modal allele length. In 2 remaining indi-
viduals, we could not successfully amplify an expanded allele,
although in both cases it was possible to amplify a single
nonexpanded allele, consistent with the presence of a non-
ampliﬁable expanded allele containing a large number of GC-
rich variant repeats (see below for additional analyses). In the
cases where we were able to obtain a historical DNA sample,
the modal allele length had nearly always noticeably increased
in size between the time of diagnosis and recruitment to the
trial (ﬁgure 1A). As expected, it was easier to estimate ePAL
from the diagnostic DNA sample obtained at an earlier age,
conﬁrming the value of these historical DNA samples.
Identificationof variant repeatswithin theCTG
arrays of the OPTIMISTIC cohort
Although the majority of patients with DM1 likely inherit
a pure CTG repeat expansion at the DMPK locus, it is known
that a subset of patients contains variant repeat interruptions
within the disease allele.31,35 Such variant repeats, most
commonly CCG and CGG, have been shown to reduce both
germline and somatic instability31 and appear to be associated
with less severe symptoms.31,35–37 Thus, we used SP-PCR to
amplify the CTG repeat tract and test for the presence of
variant repeats by post-PCR digestion with AciI (ﬁgure 1B).
AciI recognizes the sequence CCGC and cleaves both CCG
and CGG variant repeats.31 Using this approach, we identiﬁed
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variant repeats in 19 out of 248 expanded alleles (7.7%). This
included all the samples that required the addition of DMSO
to facilitate PCR ampliﬁcation. For the 2 samples for which we
could not amplify the expanded allele, we used RP-PCR31,38,39
to conﬁrm the presence of an expanded allele (ﬁgure 1C). The
presence of gaps within the repeat ladder of these 2 partic-
ipants is consistent with the existence of variant repeats within
the expanded allele. Thus, overall, the total frequency of
participants identiﬁed with variant repeats in the expanded
allele was 8.4% (21/250 [13/21 female], 95% CI
5.4%–12.7%). This included 1 pair of siblings, in both of
whom we detected variant repeats. Interestingly, we also
detected variant repeats in the daughter of a male transmitting
parent in whom we did not detect variant repeats, consistent
with de novo gain of variant repeats (ﬁgure 1B). Similarly, we
also detected variant repeats in only 1 of a pair of siblings,
consistent with either a de novo gain or loss of variant repeats
(ﬁgure 1B). Although the proportion of participants with
variant repeats appeared to diﬀer between centers (Munich 5/
65 [7.7%, 95% CI 2.8%–17.8%], Newcastle 4/52 [7.7%, 95%
CI 2.5%–19.4%], Nijmegen 9/66 [13.6%, 95% CI
6.8%–24.8%], Paris 3/67 [4.5%, 95% CI 1.2%–13.4%]), these
diﬀerences were not statistically signiﬁcant (Fisher exact test,
p = 0.32). In one participant, we detected variant repeats in
a 34-triplet large non-disease-associated allele (ﬁgure 1B).
Age at onset correlations in the
OPTIMISTIC cohort
Self-reported age at onset of symptoms was available for
229 participants and we used linear regression modeling to
Figure 1 Estimation of progenitor and modal CTG repeat length and detection of AciI-sensitive variant repeats
(A) Shown are representative small pool
PCR (SP-PCR) analyses of repeat length
variation at the DMPK CTG repeat in
blood DNA from 5 individuals. For each
participant, the analysis of 2 DNA sam-
ples is shown: historical sample taken at
time of initial diagnosis (H) and at base-
line (V2). The age at sampling for each
sample is indicated in years. The ap-
proximate positions of the molecular
weight standards converted into the
number of CTG triplet repeats are shown
on the left. The position of the estimated
progenitor allele length for each in-
dividual is indicated with the lower
dashed white line. The modal allele
length at each time point is indicated by
the upper dashed white line. For each
sample, 4 replicate PCRswere performed
with ;180–300 pg DNA. (B) Shown are
representative SP-PCR and AciI diges-
tions of the DMPK CTG repeat in blood
DNA from 7 individuals. For each partic-
ipant, 3 replicate PCRs were performed
with ;500 pg DNA, digested (+) or un-
digested (−) with AciI, resolved by aga-
rose gel electrophoresis and Southern
blot hybridized with a repeat unit probe.
The approximate positions of the mo-
lecular weight standard converted into
the number of CTG triplet repeats of
undigested products is shown on the left.
For each participant the presence (blue)
or absence (red) of AciI-sensitive variant
repeats within the expanded allele is in-
dicated by filled pedigree symbols. Note
OP177 contains AciI-sensitive variant
repeats within the non-disease-associ-
ated allele as indicated by the blue tri-
angle. (C) Detection of expanded alleles
using repeat-primed PCR (RP-PCR).
Shown are 59- and 39-RP-PCR assays for 2
participants (OP251 and OP121) in which
we were not able to amplify the ex-
panded allele using flanking primers. For
both participants, a ladder of products
extending beyond 50 repeats was ob-
served using RP-PCR, confirming the
presence of a disease-causing expan-
sion. Notably, the ladders were discon-
tinuous, consistent with the presence of
variant repeat blocking amplification
from the (CAG)5 or (CTG)5 repeat primer
at some positions within the array. The
approximate positions of the molecular
weight standard converted into the
number of triplet repeats are shown.
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Figure 2 Age at onset and somatic instability correlations
(A) Age at onset is highly correlated with estimated progenitor allele length (ePAL). The scatterplots show the relationship between ePAL and age at onset. The
relevant line of best fit under a logarithmic model for female individuals (circles, orange line), male individuals (squares, lavender line), and sex-averaged for
all individuals (black line,model 1a) (table 1) are shown. Individualswith (blue) andwithout (red) AciI-sensitive variant repeats are also depicted, alongwith the
logarithmic regression line for AciI-sensitive variant repeat carriers (blue line). (B) Effect of variant repeats on age at onset. Shown are boxplots for the
difference in observed age at onset minus predicted age at onset for Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of
Life—Standards, a Target Identification Collaboration (OPTIMISTIC) participants with (yes, blue) and without (no, red) AciI-sensitive variant repeats in their
expanded DMPK allele. Predicted age at onset was derived usingmodel 1a (Ageo = 80.3 + [−23.4 × log(ePAL)]) (table 1). Themean difference in age at onset for
participants carrying AciI-sensitive variant repeats was 13.2 years (95% confidence interval [CI] 5.7 to 20.7, 2-tailed t test t = −3.7, p = 0.0019). The bottom and
top of the box are the lower and upper quartiles, respectively. The band near themiddle of the box is themedian and the notches approximate to the 95% CI
for themedians. Thewhiskers represent the full range of observations bounded by an upper limit equal to the upper quartile plus 1.5× the interquartile range,
and a lower limit equal to the lower quartileminus 1.5× the interquartile range. Any points outside these bounds are displayed individually as small circles. (C)
Modal allele length, ePAL, and presence of AciI variant repeats. The scatterplots show the relationship between ePAL and modal allele length at the V2 time
point. Individuals with (blue) and without (red) AciI-sensitive variant repeats are indicated. (D) Sampling bias in the OPTIMISTIC cohort. The scatterplots show
the relationship between ePAL and age at onset for the OPTIMISTIC cohort (open diamonds, black line) and a family-based DM1 population characterized by
Morales et al.25 (green triangles and line). The relevant line of best fit under a logarithmic model (model 1a, table 1) is shown for each population (for the
OPTIMISTIC cohort n = 222, r2 = 0.178, p = 3.1 × 10−11 and forMorales et al., n = 137, r2 = 0.640, p < 2.2 × 10−16). Note that theMorales et al. cohort hasmore very
mildly affected participants with small expansions, and more severely affected patients with large expansions. (E) ePAL is more informative than the
diagnostic measure in predicting age at onset. The scatterplots show the relationship between age at onset and ePAL (ePAL, open diamonds and black line)
and the diagnostic allele length (diagnostic CTG,maroon diamonds and line) for theOPTIMISTIC cohort. The relevant line of best fit under a logarithmicmodel
(model 1a, table 1) is shown for each CTG measure (for ePAL n = 222, r2 = 0.178, p = 3.1 × 10−11 and for diagnostic CTG n = 105, r2 = 0.123, p = 0.00014).
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investigate genotype–phenotype relationships. As expected,25,26,40
ePAL was a major modiﬁer of age at onset (ﬁgure 2A and table 1,
model 1a, r2 = 0.178, p = 3.1 × 10−11). The presence of variant
repeats was also highly signiﬁcantly (p = 2.2 × 10−5) associated
with a later age at onset (ﬁgure 2A and table 1, model 1b, r2 =
0.240, p= 3.4 × 10−14). In order to better quantify these eﬀects, we
calculated the age at onset predicted by ePAL alone (i.e., model
1a) and compared this to the observed age at onset. The mean
diﬀerence in age at onset between individuals with and without
variant repeatswas 13.2 years (95%CI 5.7 to 20.7, 2-tailed t test t=
−3.7, p = 0.0019, ﬁgure 2B). Recently, it has been reported that
there are substantial sex-dependent diﬀerences in the relative in-
cidence and severity of some aspects of DM1.41 Similarly, we
recently reported some evidence for sex-dependent genotype–
phenotype correlations in age at onset, although these appeared to
be driven largely by an excess of mildly aﬀected transmitting
grandfathers.40 Here, sex was revealed as having a marginally
signiﬁcant eﬀect (p = 0.015) on age at onset (table 1, model 1c,
r2 = 0.257, p = 1.2 × 10−14).
Determinants of somatic instability in the
OPTIMISTIC cohort
We deﬁned the degree of somatic instability as the diﬀerence
between ePAL and the modal allele at recruitment (time point
V2). As expected,25,40 the major determinants of the degree of
somatic instability were ePAL (ﬁgure 2C), age at sampling,
and an interaction between them (table 2, model 2a, r2 =
0.560, p < 2.2 × 10−16). Previously, we also demonstrated in
one family that the presence of variant repeats reduced the
degree of somatic instability.31 Likewise, here the presence or
absence of variant repeats (ﬁgure 2C) was revealed as a highly
signiﬁcant (p = 4.9 × 10−8) additional measure in the re-
gressionmodel (table 2, model 2b, r2 = 0.610, p < 2.2 × 10−16).
In contrast, sex of the participant (p = 0.48) was found not to
Table 1 Age at onset regression models
Model Adjusted r2 p Value Measure Coefficient
Standard
error t Statistic p Value
1a Ageo = β0 + β1Log(ePAL), n = 222 0.178 3.1 × 10
−11 Intercept, β0 80.3 7.9 10.2 <2 × 10
−16
Log(ePAL), β1 −23.4 3.3 −7.0 3.1 × 10
−11
1b Ageo = β0 + β1Log(ePAL) +
β2Variant repeats, n = 222
0.240 3.4 × 10−14 Intercept, β0 86.6 7.7 11.2 <2 × 10
−16
Log(ePAL), β1 −26.5 3.3 −8.0 5.5 × 10
−14
Variant repeats,β2 13.8 3.2 4.3 2.2 × 10
−5
1c Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex, n = 222
0.257 1.3 × 10−14 Intercept, β0 85.6 7.7 11.2 <2 × 10
−16
Log(ePAL), β1 −27.0 3.3 −8.3 1.4 × 10
−14
Variant repeats,β2 14.6 3.2 4.6 7.0 × 10
−6
Sex, β3 3.8 1.6 2.4 0.015
1d Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex +
β4Standardised residuals (SI,
model 2b), n = 222
0.260 2.9 × 10−14 Intercept, β0 85.7 7.6 11.2 <2 × 10
−16
Log(ePAL), β1 −27.0 3.3 −8.3 1.2 × 10
−14
Variant repeats,β2 14.5 3.2 4.6 8.2 × 10
−6
Sex, β3 3.8 1.6 2.4 0.017
Standardized
residuals (SI), β4
−1.0 0.8 −1.3 0.186
1e Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex +
β4Standardised residuals (SI,
model 2b) + β4Standardised
residuals (SI, model 2b) ×
Log(ePAL), n = 222
0.304 <2.2 × 10−16 Intercept, β0 104.0 8.8 11.8 <2 × 10
−16
Log(ePAL), β1 −34.8 3.8 −9.2 <2 × 10
−16
Variant repeats,β2 16.6 3.1 5.3 2.7 × 10
−7
Sex, β3 3.6 1.5 2.3 0.020
Standardized
residuals (SI), β4
25.0 6.8 3.7 2.9 × 10−4
Standardized
residuals (SI) ×
log(ePAL), β5
−11.3 2.9 −3.9 1.5 × 10−4
Abbreviations: Ageo = age at onset; SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each model, and
the coefficient (β), standard error, t statistic, and statistical significance (p) associated with each measure in the model. The coefficient (β) provides an
indication of the relative weight of the contribution of eachmeasure to themodel and its associated standard error. The t statistic and corresponding p value
provide an indication of the statistical significance that the measure is adding explanatory power to the model.
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improve the regression model (table 2, model 2c, r2 = 0.609,
p < 2.2 × 10−16).
The role of somatic instability on age at onset
in the OPTIMISTIC cohort
As longer inherited allele lengths precipitate an earlier age at onset
in DM1, and as somatic instability is highly biased toward expan-
sions, it seems logical to expect that individual-speciﬁc diﬀerences
in the rate of expansion should modify age at onset. Indeed, we
previously established evidence for such an eﬀect in amixed cohort
of patients with DM1 from Scotland, the United States, and Costa
Rica,25 and conﬁrmed this eﬀect in a largeCosta Rican cohort.40 In
theOPTIMISTIC cohort, incorporating the standardized residuals
of somatic instability derived from model 2b into the age at onset
model (table 1, model 1d, r2 = 0.260, p = 3.0 × 10−14) improved
the r2 value slightly from model 1c, but the standardized residuals
of somatic instability did not reach statistical signiﬁcance as
ameasure (p= 0.19).However, when the standardized residuals of
somatic instability were included with an interaction with ePAL,
themodel was improved further (table 1, model 1e, r2 = 0.304, p <
2.2 × 10−16) and both the standardized residuals of somatic in-
stability alone (p = 2.9 × 10−4) and the interaction with ePAL (p =
1.5 × 10−4) were revealed as highly signiﬁcant measures.
Genetic correlations with progressive
phenotypes in the OPTIMISTIC cohort
As part of the OPTIMISTIC protocol, several DM1 pheno-
types were also quantiﬁed at baseline using a variety of direct
and indirect (i.e., questionnaires) assessment tools.27 To in-
vestigate the genotype–phenotype relationships of these
progressive phenotypes, we applied a model selection process
incorporating ePAL, residual variation in somatic instability,
variant repeats, sex and age at baseline, and interactions be-
tween ePAL, residual variation in somatic instability, and age
at baseline (table 3). Highly signiﬁcant associations with eﬀect
sizes comparable to those observed with age at onset were
revealed for many measures (table 3 and ﬁgure 3), including
the Muscle Impairment Rating Scale (MIRS, r2 = 0.32, p = 2.6
× 10−19), the OPTIMISTIC primary outcome, the DM1-
Activ-c score (r2 = 0.23, p = 2.9 × 10−13), and key secondary
outcomes such as the 6-MinuteWalk Test (6-MWT, r2 = 0.31,
p = 2.3 × 10−18), physical activity (accelerometry, mean, r2 =
0.25, p = 3.9 × 10−10, and most active 5-hour, r2 = 0.25, p = 8.9
× 10−12), the Trail-Making Test (TMT-A, r2 = 0.23, p = 2.2 ×
10−14, and TMT-B, r2 = 0.24, p = 4.5 × 10−12), and the Stroop
interference score (r2 = 0.21, p = 2.8 × 10−12). Moderate
associations were observed for the Adult Social Behavior
Questionnaire (ASBQ, r2 = 0.11, p = 1.6 × 10−4), the Apathy
Evaluation Scale–Clinician Version (r2 = 0.10, p = 5.1 × 10−5),
the Fatigue and Daytime Sleepiness Scale (FDSS) (r2 = 0.09,
p = 2.9 × 10−5), the Myotonic Dystrophy Health Index total
score (r2 = 0.09, p = 3.4 × 10−5), and Self-Eﬃcacy–Scale 28 for
Fatigue (r2 = 0.07, p = 2.2 × 10−4). Only weak or statistically
nonsigniﬁcant associations were observed for a number of
measures, including for van Sonderen Social Support List
(SSL) (SSL—Discrepancies [SSL-D], SSL—Interactions
Table 2 Regression models of the determinants of the degree of SI
Model Adjusted r2 p Value Measures Coefficient
Standard
error t Statistic p Value
2a Log(SI) = β0 + β1Log(ePAL) +
β2Ages +β3Log(ePAL) × Ages,
n = 247
0.560 <2.2 × 10−16 Intercept, β0 1.72 0.73 2.37 0.019
Log(ePAL), β1 0.20 0.30 0.66 0.509
Ages, β2 −0.05 0.01 −3.73 2.4 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 3.90 1.3 × 10
−4
2b Log(SI) = β0 + β1Log(ePAL) +
β2Ages + β3Log(ePAL) × Ages
+ β4VariantRepeats, n = 247
0.610 <2.2 × 10−16 Intercept, β0 1.50 0.69 2.19 0.029
Log(ePAL), β1 0.29 0.28 1.03 0.304
Ages, β2 −0.05 0.01 −3.94 1.1 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 4.17 4.2 × 10
−5
Variant repeats, β4 −0.39 0.07 −5.63 4.9 × 10
−8
2c Log(SI) = β0 + β1Log(ePAL) +
β2Ages + β3Log(ePAL) × Ages
+ β4VariantRepeats + β5Sex,
n = 247
0.609 <2.2 × 10−16 Intercept, β0 1.49 0.69 2.17 0.031
Log(ePAL), β1 0.30 0.28 1.06 0.292
Ages, β2 −0.05 0.01 −3.92 1.2 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 4.16 4.5 × 10
−5
Variant repeats, β4 −0.39 0.07 −5.67 4.1 × 10
−8
Sex, β5 −0.02 0.04 −0.71 0.481
Abbreviation: SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each model, and
the coefficient (β), standard error, t statistic, and statistical significance (p) associated with each measure in the model.
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Table 3 Regression models of the determinants of progressive phenotypes
Dependent variable Direction
Overall model
Parameter
Age Log(ePAL)
n r2 p Value β p Value β p Value
Muscle impairment rating scale L 247 0.32 3 × 10−19 −0.06 0.08 −0.1 0.92
6-min walk test distance (m) H 246 0.31 2 × 10−18 2.89 0.57 −62.7 0.56
Physical activity (most active 5-h) H 198 0.25 9 × 10−12 −1.11 5 × 10−9 −60.0 5 × 10−11
Physical activity (mean) H 198 0.25 4 × 10−10 −0.10 0.87 −16.4 0.23
Trail making test—A L 234 0.24 5 × 10−12 3.14 0.20 97.6 0.06
Trail making test—B L 242 0.23 2 × 10−14 0.82 2 × 10−15 22.4 3 × 10−6
DM1-Activ-c H 246 0.23 3 × 10−13 0.43 0.57 −3.3 0.84
Log (Stroop interference score) L 238 0.21 3 × 10−12 0.02 3 × 10−12 0.7 2 × 10−5
Adult social behavioural questionnaire L 201 0.11 0.0002 0.99 0.17 31.5 0.03
Apathy evaluation scale—clinician score L 241 0.10 5 × 10−5 0.45 0.38 20.0 0.07
Fatigue and daytime sleepiness scale L 242 0.09 3 × 10−5 1.04 0.04 15.6 0.15
Myotonic dystrophy health index L 245 0.09 3 × 10−5 0.43 2 × 10−5 17.7 0.0003
Self-efficacy scale 28 for fatigue H 241 0.07 0.0002 −0.04 0.02 −2.4 0.002
Van Sonderen social support—discrepancies L 196 0.05 0.01 0.22 0.02 9.7 0.04
Illness cognition questionnaire H 237 0.04 0.02 0.17 0.45 3.5 0.47
Van Sonderen social support—interactions H 216 0.04 0.02 −0.20 0.06 −10.7 0.09
Individualised neuromuscular quality of life
questionnaire—subscale quality of life
L 245 0.04 0.03 −3.56 0.07 −63.2 0.13
Checklist individual strength—fatigue subscale L 247 0.03 0.01 0.07 0.04
Sickness impact profile L 156 0.03 0.02 78.6 0.02
McGill pain score L 233 0.03 0.02 15.4 0.03
Jacobsen fatigue catastrophizing scale L 241 0.02 0.03 0.09 0.06 5.4 0.01
Apathy evaluation scale—informant version L 99 0.02 0.32
Beck depression inventory—fast screen L 243 0.01 0.18 0.16 0.36 3.8 0.31
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Table 3 Regression models of the determinants of progressive phenotypes (continued)
Dependent variable Direction
Overall model
Parameter
Age Log(ePAL)
n r2 p Value β p Value β p Value
Illness management questionnaire L 241 0.01 0.28 0.44 0.42 11.1 0.33
Van Sonderen social support—negative interactions L 218 0.00 0.35 1.4 0.22
Physical activity (least active 5-hour) L 198 −0.02 0.82
Caregiver strain index L 98 −0.07 0.98
Dependent variable
Standardized
residuals (SI,
model 2b) Variant repeats Sex (Male) Log(ePAL) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b)
Standardized
residuals (SI,
model 2b) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b) ×
Age
β p Value β p Value β p Value β p Value β p Value β p Value β p Value
Muscle impairment rating scale 0.3 2 × 10−8 −0.8 6 × 10−5 0.04 0.02
6-min walk test distance (m) −25.2 0.0001 115.2 1 × 10−5 51.9 0.0001 −3.24 0.13
Physical activity (most active 5-h) −4.3 0.03 22.2 0.003 9.0 0.02
Physical activity (mean) 33.6 0.12 9.6 0.001 2.2 0.13 −0.14 0.60 −14.5 0.12 −0.64 0.14 0.26 0.17
Trail making test—A −158.8 0.06 −30.2 0.007 −0.45 0.66 71.4 0.05 2.93 0.09 −1.32 0.08
Trail making test—B −8.9 0.04
DM1-Activ-c −1.6 0.10 12.4 0.001 −0.48 0.14
Log (Stroop interference score) −0.5 0.001
Adult social behavioural questionnaire −88.5 0.0004 −5.6 0.07 4.4 0.007 −0.40 0.19 37.0 0.0007 1.88 0.001 −0.80 0.001
Apathy evaluation scale—clinician score −46.8 0.009 −7.0 0.002 −0.15 0.49 22.5 0.004 0.81 0.02 −0.39 0.01
Fatigue and daytime sleepiness scale −6.5 0.01 −3.7 0.005 −0.36 0.09
Myotonic dystrophy health index 1.7 0.10 −6.6 0.11
Self-efficacy scale 28 for fatigue −0.5 0.01 0.8 0.02
Van Sonderen social support—discrepancies −6.1 0.08 3.6 0.08
Illness cognition questionnaire 16.7 0.04 1.4 0.007 −0.08 0.44 −7.5 0.03 −0.33 0.04 0.15 0.04
Van Sonderen social support—interactions 21.9 0.03 6.2 0.15 −5.6 0.01 −9.6 0.03
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Table 3 Regression models of the determinants of progressive phenotypes (continued)
Dependent variable
Standardized
residuals (SI,
model 2b) Variant repeats Sex (Male) Log(ePAL) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b)
Standardized
residuals (SI,
model 2b) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b) ×
Age
β p Value β p Value β p Value β p Value β p Value β p Value β p Value
Individualised neuromuscular quality of life
questionnaire—subscale quality of life
90.1 0.19 1.78 0.04 −42 0.16 −2.26 0.10 1.07 0.08
Checklist individual strength—fatigue subscale −4.0 0.01 0.09 0.006
Sickness impact profile
McGill pain score −6.5 0.06
Jacobsen fatigue catastrophizing scale
Apathy evaluation scale—informant version
Beck depression inventory—fast screen −17.1 0.007 −0.06 0.42 7.6 0.005 0.29 0.02 −0.13 0.02
Illness management questionnaire −25.6 0.17 −0.18 0.44 11.5 0.15 0.64 0.09 −0.29 0.08
Van Sonderen social support—negative
interactions
−3.6 0.10 1.6 0.09
Physical activity (least active 5-hour)
Caregiver strain index
Abbreviation: SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each overall model for each dependent variable (phenotype), and the coefficient (β)
and statistical significance (p) associated with eachmeasure in themodel and their interactions (×). The direction indicates whether a higher (H) or lower (L) score for the phenotype represents a better (i.e., “healthier”) result for
the individual. Note that the blank cells correspond to independent variables that were rejected by the model selection procedure, as their inclusion did not significantly improve the overall regression model for the given
phenotype.
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[SSL-I], and SSL—Negative Interactions [SSL-N]), CIS-
Fatigue, the McGill Pain Questionnaire, the Sickness Impact
Proﬁle, and the Beck Depression Inventory—fast screen
(BDI-fs), all r2 < 0.05, p > 0.01, and n > 150 (table 3). For all
of the highly associated measures (r2 > 0.15), age, ePAL, and
presence of variant repeats were revealed as important ex-
planatory variables (table 3). The relative degree of somatic
mosaicism was also an important explanatory variable for all
Figure 3 Estimated progenitor allele length (ePAL) and variant repeat correlations with age-dependent phenotypes
The scatterplots show the relationship between ePAL and a number of age-dependent phenotypes. The relevant line of best fit under a logarithmic model
(dependent variable = β0 + β1Log[ePAL]) for female individuals (circles, orange line), male individuals (squares, lavender line), and sex-averaged for all
individuals (black line) are shown. Individuals with (blue) and without (red) AciI-sensitive variant repeats are also depicted, along with the logarithmic
regression line for AciI-sensitive variant repeat carriers (blue line).
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bar the Stroop interference score and TMT-A. Sex was also an
important modiﬁer for the 6-MWT and physical activity
(accelerometry, mean, and most active 5-hour) (table 3).
Discussion
We analyzed the length and dynamics of the disease-causing
CTG repeat expansion in the DMPK gene to reveal the pri-
mary genetic determinants of symptomatic variation in the
OPTIMISTIC cohort. As expected, we were able to establish
ePAL as a major determinant of self-reported age at onset (table
1, model 1a). However, it is notable that the proportion of
variance in age at onset explained by ePAL (r2 = 0.178) was
much lower than observed in previous studies (e.g., r2 = 0.640 in
Morales et al.25). This is attributable to the eligibility constraints
for recruitment to OPTIMISTIC that dictated that participants
must be aged at least 18 years, have severe fatigue (CIS-Fatigue
severity score ≥35), but nonetheless retain the ability to walk
independently, and be able to provide informed consent and be
motivated to undergo CBT. Thus, OPTIMISTIC has fewer
very mildly aﬀected participants with small expansions, and
fewer severely aﬀected patients with very large DM1 expansions
(ﬁgure 2D). Selection of moderately aﬀected patients is likely to
be a common feature of many of the early DM1 trials, sug-
gesting that the genetic characteristics and phenotypic rela-
tionships of the OPTIMISTIC cohort will likely be
representative of other DM1 trial cohorts. Although age at onset
is an important aspect of the disease phenotype, it is somewhat
subjective in its assessment as it may depend on patient recall,
patient knowledge and relative cognition, and insight.42 More-
over, age at onset is unlikely in the near term to be an outcome
measure in clinical trials. We have also revealed that ePAL is an
important contributor to multiple age-dependent phenotypes
that were also assessed as part of the OPTIMISTIC protocol,
including key measures of muscle function and activity such as
the MIRS, 6MWT, DM1-Activ-c, and accelerometry data, and
key CNS phenotypes such as the TMT and Stroop test. In
contrast, other phenotypes such as SSL-D/I/N, CIS-Fatigue,
McGill pain, and BDI-fs were not well-explained by genetic
factors. It seems reasonable to assume that in general symp-
toms that are strongly associated with the causative mutation in
DM1 are most directly linked to the underlying disease process
and may be the most responsive to therapeutic interventions
targeting the underlying pathology. It is also possible that some
of the more subjective self-reported measures may also be
compromised by reduced patient insight,42 further confound-
ing genotype to phenotype associations.
For many years it was assumed that expanded alleles at the
DMPK locus comprised pure CTG repeat arrays. However, it
has become apparent that a subset of DM1 expansions con-
tains variant repeats.31,35,37,43,44 Previous estimates for the
frequency of such variants in unselected DM1 cohorts vary
from ;3% to 5%.31,35–37 Here, we determined the overall
frequency of variant repeats as 8.4% of the total cohort (21/
250). In the Nijmegen subcohort, the frequency of variants
was 13.6% (9/66, 95% CI 6.8%–24.8%), while in the Paris
subcohort it was only 4.5% (3/67, 95% CI 1.2%–13.4%).
Although there was 1 pair of siblings from Nijmegen who
shared variant repeats, none of the other participants from
Nijmegen with variant repeat containing expanded alleles
were known to be related to each other. Thus, chance sam-
pling of one or a few large families segregating variant repeat
alleles does not explain the higher frequency of variant repeat
alleles observed in the Nijmegen subcohort. While it is pos-
sible that this may reﬂect some sort of site-speciﬁc recruitment
bias, this diﬀerence was not statistically signiﬁcant and may
simply represent random sampling error. Regardless, the
presence of variant repeats clearly inﬂuences disease severity,
with individuals carrying such alleles having an age at onset
delayed by an average of ;13 years relative to that predicted
using the 1a regression model. It is possible that the reduced
disease severity observed inDM1 carriers of repeat alleles led to
their overselection in OPTIMISTIC, conceivably mediated by
a reduced neuropsychological eﬀect of the disease and higher
motivation among this subcohort. In addition to modifying age
at onset, these data also reveal the protective eﬀect of variant
repeats on many of the progressive phenotypes likely to be
outcomes in clinical trials. If variant repeat carriers are over-
recruited, this may reduce sensitivity to correctly evaluate ef-
ﬁcacy of a therapeutic intervention in a clinical trial. These
considerations suggest that testing for the presence of variant
repeats should be included in DM1 trial design.
Recently, it has been demonstrated that the absolute frequency
and severity of diﬀerent aspects of the complex DM1 phenotype
are diﬀerentially expressed in male and female patients.41 Simi-
larly, we have presented preliminary evidence that suggest there
may also be subtle repeat-length-independent sex eﬀects on age
at onset.40 Here, we also observed a marginally signiﬁcant sex
eﬀect (p = 0.015) when including sex as a measure in the age at
onset model (table 1, model 1c). However, the direction of this
eﬀect was the opposite to that previously observed. These
observations suggest sex has only a subtle eﬀect on overall age at
onset. Nonetheless, sex was revealed as an important cofactor for
some phenotypes such as the 6MWT, the ASBQ, and the FDSS
(table 3) and should be considered as an important factor in
clinical trials.
We recently demonstrated that residual variation in somatic
instability not accounted for by age at sampling and ePAL was
inversely correlated with residual variation in age at onset not
accounted for by ePAL, i.e., patients in whom the repeat
expands more rapidly in the soma have earlier ages at onset
than expected.25,40 Here, we have used SP-PCR to calculate
the modal length change during the lifetime of the patient as
a measure of somatic instability and shown variation in this
measure is explained by the expected measures, i.e., ePAL, age
at sampling, and a strong interaction between them (table 2,
model 2a). In addition, we have conﬁrmed that somatic in-
stability is reduced by the presence of variant repeats. We have
also provided additional evidence that somatic mutational
dynamics directly modify disease severity, with residual
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variation in somatic instability accounting for approximately
4.7% of the total variation in age at onset and detectably
contributing to many age-dependent phenotypes and con-
ﬁrming somatic expansion as an important therapeutic target.
Traditionally, DM1 is diagnosed using Southern blot hybrid-
ization of restriction digested genomic DNA. The low pre-
dictive value of this measure and additional complications
mediated by a failure to fully consider the eﬀects of age-
dependent somatic expansion on interpreting intergenerational
length changes prompted the International Myotonic Dystro-
phy Consortium to recommend that families not be oﬀered
predictive phenotypic information based on the number of
CTG repeats.12 While this recommendation is not universally
observed, this suggestion, coupled with the technical challenges
of Southern blot hybridizations and the availability of a simple
yes/no RP-PCR test,39 has led to a situation where many di-
agnostic laboratories do not even attempt to measure the
number of CTG repeats. For example, within the OPTIMIS-
TIC cohort, a diagnostic CTG repeat length was available for
only 121 out of 255 participants. As expected, the predictive
value of this measure was relatively low, the diagnostic CTG
length measure accounting for only 12% of the variation in age
at onset (ﬁgure 2E, n = 103, r2 = 0.123, p = 0.00014). This
contrasts sharply with the;30% of variation accounted for by
estimating progenitor allele length, quantifying somatic mosa-
icism, and determining the presence or absence of variant
repeats (table 1, model 1e). These data suggest that it may be
time to revisit the recommended diagnostic criteria for DM1
and the potential value of reporting more informative prog-
nostic information to families by estimating progenitor allele
length and testing for the presence of variant repeats.
We have deﬁned the genetic characteristics of the DMPK
expansion in the cohort of patients with DM1 recruited to the
OPTIMISTIC clinical trial. These baseline data have already
yielded important insights into genotype to phenotype rela-
tionships in DM1 and should provide a route to determining
the possible eﬀect of genotype on intervention response and
a basis for genetic stratiﬁcation of DM1 trial participants.
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